Company Overview and News
Cormorant Asset Management, LLC Buys Nektar Therapeutics Inc, Sage Therapeutics Inc, Rocket Pharmaceuticals Inc, Sells Juno Therapeutics Inc, Proteostasis Therapeutics Inc, bluebird bio Inc
SAGE RCKT MRTX ONCS PTI
Shionogi & Co. will partner with Sage Therapeutics to develop and commercialize Sage’s SAGE-217 to treat major depressive disorder (MDD) and other indications in Japan, Taiwan, and South Korea, through a collaboration that could generate up to $575 million-plus for Sage. [© Paolese/Fotolia]
Days after the U.S. Food and Drug Administration (FDA) provided an expedited path forward for SAGE Therapeutics’ depression treatment SAGE-217, the company snagged a deal worth $575 million from Japanese pharma firm Shionogi & Co., Ltd., to market the treatment in parts of Asia.
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Sage Therapeutics announced that the FDA will let it run a shorter study so that it may gain a quicker path to approval for its depression drug SAGE-217.
U.S. stock-market indexes traded tentatively higher Tuesday morning as investors shifted their attention away from a landmark meeting between President Donald Trump and Kim Jong Un to the start of a series of important central-bank meetings kicking off later in the day with the Federal Reserve.
Following a meeting with the U.S. Food and Drug Administration (FDA) SAGE Therapeutics is seeing the goal line for potential expedited approval of its major depressive disorder (MDD) and postpartum depression (PPD) treatment, SAGE-217 (brexanolone).
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
A spike in suicide rates in the United States has cast fresh light on the need for more effective treatments for major depression, with researchers saying it is a tricky development area that has largely been abandoned by big pharmaceutical companies.
CHICAGO (Reuters) - The suicides this week of Anthony Bourdain and Kate Spade have cast fresh light on the need for more effective treatments for major depression, an area that has been largely abandoned by big pharmaceutical companies.
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs), such as Prozac and Zoloft, or serotonin-norepinephrine reuptake inhibitors (SNRIs), like Pristiq or Efexor. But there are still individuals who do not respond well to these drugs and the industry continues to work on developing better and alternative treatments for depression. There has been quite a bit of activity in this area recently.
SAGE MKGAF MKGAY VTGN
The futures traded higher again Wednesday morning, perhaps in part because of the fact that the Russell 2000 hit an all-time high on Tuesday. That is a move that no doubt caught the eye of many traders, as we could be seeing a shift to smaller capitalization companies after years of large caps leading the way. With a stronger dollar, small caps, with their domestic focus, could be the top play going forward.
ALKS INPAP WDC VRX MDT SAGE VRX IP TSLA TRI CI FSLR
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to SAGE / Sage Therapeutics, Inc. on message board site Silicon Investor.
as of ET